Collectively, a meta-analysis of these trials—including 60,080 patients with diabetes and cardiovascular disease—indicates that GLP-1 agonists reduce HF hospitalizations by 10–11% [240,241]. The gene discussed is GLP1R; the disease is diabetes mellitus.